Empowering Women's Health: The Women's Digital Health Management Forum at the 7th Future Healthcare 100 Summit Successfully Concludes

From May 5 to 7, 2023, the “7th Future Healthcare Top 100 Conference” was held at the Zhangjiang Science Hall in Shanghai. Themed “Regardless of East or West,” the conference featured three main forums and more than 30 sub-forums. Over the three-day event, participants focused on cutting-edge scientific and technological achievements, world-class medical challenges, strategies of leading enterprises, popular niche sectors, and new trends in venture capital and investment. On the afternoon of May 7, the Forum on the Development of Digital Health Management for Women was successfully held. This forum invited companies from the women’s health industry to discuss comprehensive lifecycle health management, including the diagnosis and treatment of common female diseases and cancer screening.

"AI Empowers Female Pelvic Floor Rehabilitation"

Du Hui | CMO of Medlander

Du Hui, Chief Marketing Officer of Mailande, stated that pelvic floor dysfunction has become one of the five major chronic diseases threatening women’s health. Characterized by high prevalence yet low consultation rates, the current capture rate of the potential female population eligible for pelvic floor treatment is less than 7.61%. Du Hui pointed out that the key challenges in addressing pelvic floor disorders include high consumable costs, complex equipment operation, steep learning curves, and fragmented diagnostic and treatment data. He proposed solutions focused on “developing new consumable technologies to reduce costs, enhancing equipment intelligence and ease of use, and digitizing equipment to integrate with the ‘Internet Plus’ concept.” Finally, he clarified that Mailande’s overall solution strategy centers on the niche field of pelvic floor rehabilitation, driven by customer needs and underpinned by intelligent core logic.

“Understanding the Upgraded Needs and Development Trends in Women’s Health in the ‘She Era’”

Wang Ruilin | Vice President and Planning Director, Dayima App, Youlehua (Beijing) Network Technology Co., Ltd.

Wang Ruilin, Vice President of Youlehua (Beijing) Network Technology Co., Ltd. and the Dayima App, stated that Dayima is China’s No. 1 female physiological health software for tool-based tracking, ovulation prediction, and the prevention of physiological symptom-related diseases. Centered on the full-lifecycle health needs of women—including menstruation, preconception, pregnancy, and motherhood—Dayima’s one-stop female health service ecosystem provides core services in female health management, encompassing tracking, community interaction, e-commerce, and healthcare, thereby constructing a closed-loop, one-stop ecological service for women’s health. Wang Ruilin introduced Dayima as a leader in China’s female health management sector, with a total registered user base of 130 million, 560 health topics, a peak topic participation of 18.55 million users, 40 million monthly active users, and 6 million daily active users.

“A Full-Cycle Women’s Health Service System Under New Consumer Trends”

Zhou Li | Partner at Weimai, General Manager of the Strategic Development Center

Zhou Li, Partner at Weimai and General Manager of the Strategic Development Center, stated that by leveraging the “Weimai + Hospital + Ecosystem” model, the company is building a comprehensive health service system covering the entire female life cycle. This system provides health services tailored to the physiological and pathological needs of women throughout their lives. In terms of childbirth, Weimai has established a medical and health service system for women of childbearing age, offering integrated full-cycle management for pregnancy and childbirth, care services during pregnancy and delivery, and smart home-based postpartum rehabilitation management. For child-rearing, Weimai has independently developed the “Smart Pediatric Medical Health Management Platform” to build a medical and health service system for infants and children, providing a series of infant and child health intervention services. In the area of beauty and wellness, Weimai has established service systems for female endocrinology and medical aesthetics, female constitutional conditioning, and a new generation of public hospital-based whole-course disease management services.

“AI-Empowered Screening, Diagnosis, and Treatment of Breast Cancer”

Ying Cao | Vice President, Yizhun Medical AI

Cao Ying, Vice President of Yizhun Intelligent, stated that standardized screening is a crucial approach to achieving early diagnosis and treatment of breast cancer, thereby improving survival rates. She introduced Yizhun Intelligent’s integrated smart solution for breast cancer screening, diagnosis, and treatment, which focuses on female breast cancer. The solution addresses multiple aspects of screening, diagnosis, and treatment, while simultaneously covering various dimensions such as imaging quality control, scientific research, and teaching. It provides full-stack coverage of the entire workflow, including image acquisition, imaging analysis, guidance for minimally invasive interventional procedures, automated reporting, and education and training.

“NGS Technology Empowers Precision Diagnosis and Treatment of Gynecologic Tumors”

Chen Yan | Founder, Chairman, and General Manager of Feishuo Bio

Chen Yan, Founder, Chairman, and General Manager of Feishuo Biotechnology, stated that expert consensus recommends next-generation sequencing (NGS) as the detection method for molecular subtyping in all diagnosed endometrial cancer patients and for biomarker testing in cases of recurrent or metastatic endometrial cancer. Mr. Chen introduced that Feishuo Biotechnology’s molecular subtyping product for endometrial cancer employs high-throughput sequencing to analyze the exonuclease domain of the POLE gene, while simultaneously assessing mismatch repair (MMR) genes and microsatellite instability (MSI) status. With a sequencing depth of 5000×, the assay can detect mutations with frequencies as low as 1%. MSI testing can be completed using a single tissue sample; when compared against 62 national reference standards, the concordance rate reached 100%. The test can identify common microsatellite shifts in endometrial cancer. Utilizing the proprietary RingCap® library preparation technology, the method is simple, requires fewer operational steps, and offers a short turnaround time for reporting.

“Practices and Reflections on Health Management Across the Female Life Cycle”

Cheng Yongsheng | Executive Partner, Noah Medical

Cheng Yongsheng, Executive Partner of Noah Healthcare, introduced that the company provides a one-stop medical service covering the full lifecycle of women’s and children’s health, spanning preconception care, pregnancy, postpartum recovery, and childcare. With the “pediatric segment” serving as the customer acquisition channel and the “women’s health segment” as the core profit driver, Noah Healthcare adopts a development model combining “professional medical services” with “consumer-oriented healthcare.” The company focuses on expanding its core business areas, including eugenics and optimal prenatal care, postpartum and pediatric rehabilitation, dentistry, ophthalmology, skin management, pediatric endocrinology, and high-end gastrointestinal endoscopy check-ups, thereby creating standardized and easily replicable sub-specialty programs. He further stated that through Noah Healthcare’s Internet Hospital, the company offers integrated diagnostic and treatment HIS system services along with unified platform services (a SaaS solution integrating customer service, supply chain, payment settlement, big data support, and an online marketplace). This enables an “online-to-offline (O2O) integrated” smart healthcare service system for offline chain clinics and physician studios.

With this, the "Forum on the Development of Digital Health Management for Women" came to a successful conclusion. The FemTech industry focused on women's health is rising against the wind. Although from the perspective of the broader healthcare industry, the emerging sector of digital health for women is relatively small, there remains significant room for further exploration in niche segments and innovation. It is hoped that, empowered by technologies such as big data, artificial intelligence, cloud computing, and the Internet of Things, the domestic market for digital health management for women will usher in a "China Era."